Indigenous Nutritional Supplements for Pregnancy to Improve Resilience in Environmental Heat (INSPIRE)

March 19, 2026 updated by: Junaid Iqbal, Aga Khan University

The purpose of this study is to learn whether a simple, traditional, and balanced meal made from local foods, eaten once a day during pregnancy, can help women in rural Pakistan stay healthier in hot weather and give birth to healthier babies. Climate change has made heat a serious challenge for pregnant women, especially in areas with limited resources. This study will explore whether an indigenous meal that is culturally acceptable and easy to prepare can improve resilience to heat stress and support better outcomes for both mothers and newborns.

The study will focus on two main questions:

  • Can this daily balanced meal reduce the harmful effects of heat stress during pregnancy?
  • Does it improve newborn health, especially birth weight?

Researchers will compare women who eat the balanced local meal every day with women who continue their usual meals. They will check changes in women's health, levels of key vitamins and nutrients, and their babies' birth outcomes.

During the study, participants will:

  • Either eat the balanced local meal daily or continue their usual meals.
  • Share information on their health, diet, and heat exposure.
  • Provide small samples, such as blood and stool, to study nutrient levels and gut health.
  • Have their newborns' health and growth measured at birth.

Study Overview

Detailed Description

This study will use a quasi-experimental design to study if the effects of an indigenous heat-mitigating balanced dietary intervention on maternal health and neonatal development when implemented from preconception to delivery in a region with high temperatures.

The study will recruit 292 women of reproductive age who plan to become pregnant and assign them to either the intervention group or the comparison group in a 1:1 ratio. The intervention group will receive one customized indigenous heat-mitigating balanced diet as daily lunch meal (~1,000 kilocalories). The comparison group will continue their usual dietary practices while receive routine antenatal care and dietary counseling services according to national guidelines.

The intervention diet plans have been designed through review of dietary recommendations and published evidence, combined with community consultations to ensure feasibility and cultural acceptability. The food choices were established according to three criteria which required foods to have high nutrient content and be affordable and accessible within the local area. The meal composition includes whole grains, lentils, legumes, green leafy vegetables, dairy products, fermented foods, fish, and other culturally acceptable animal-source foods. A 14-day rotating menu will be implemented. The intervention will begin at least one month prior to conception and continue until delivery.

Meals will be prepared in kitchen in field site's office set up specially for meals preparation. Local chefs will be hired and counselled to prepare meals ensuring proper hygiene and following study's diet plans. Study data collectors will distribute meals to the participants. The team will use attendance records, intervention adherence forms, telephone follow-up and home visits to monitor intervention delivery. The team will organize home delivery services when they become essential.

The research team will evaluate maternal health at the end of each trimester starting from the time of conception until the end of pregnancy. Data will be collected through three different methods which include anthropometer, vitals assessments and testing blood samples for hemoglobin levels using point of care testing device (HemoCue 301+) and specific micronutrients & inflammatory markers (Vitamin A, D, B9, B12, Zinc, Ferritin and CRP). The research team will collect stool samples to investigate gut microbiome composition through molecular techniques. The study will use weather stations, thermal drone cameras and wearable devices (FitBit) to measure heat exposure while linking those measurements to local weather patterns.

At delivery, neonatal anthropometric measurements will be obtained using standardized procedures. Study staff will collect cord blood samples which will then undergo biomarker analysis. Moreover, placental tissues will be collected for both gross examination and transcriptomic analysis.

For safety purposes, all individuals will be monitored carefully for food allergies by conducting regular assessments and establishing health facility connections to treat any medical complications. The study allows participants to join voluntarily while they maintain their right to leave at any moment without losing access to standard medical treatment.

The study has received ethical approval from the Aga Khan University Ethical Review Committee (Reference: 2024-10697-3239) and the National Bioethics Committee of Pakistan (Reference: 4-87/NBCR-1220/24-25/836). Written informed consent will be obtained prior to enrollment. Data will be managed in accordance with institutional confidentiality and data protection policies.

Study Type

Interventional

Enrollment (Estimated)

292

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Women aged 18-45 years belonging to a low to middle socioeconomic status, residing in Mithi, Districts in Sindh.
  2. Planning to conceive within the study time frame and expect to become pregnant within four months of starting nutritional intervention.
  3. Women who confirm their pregnancy during the first trimester i.e., before 8 weeks of gestational age.

Exclusion Criteria:

  1. Women using long-lasting contraceptives such as IUDs, implants, and injectable methods like Depo-Provera.
  2. Women with a history of multiple miscarriage or stillbirths.
  3. Women with known chronic diseases, such as cardiovascular disorders, hepatic disorders, renal disorders, and infectious diseases.
  4. Women suffering from severe malnutrition (WHO: Underweight i.e., having BMI < 16 Kg/m2 or obese having BMI ≥ 30 Kg/m2).
  5. Women having severe anemia (WHO: Severe anemia i.e., Hb < 7g/dL).
  6. Women currently enrolled in BISP supplementation programs or taking any supplements other than iron and folic acid (IFA) will be excluded from the study.
  7. Those who do not become pregnant within three months of supplementation during pre-conception.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Indigenous Balanced Diet Arm
Participants in this arm will receive minimally modified culturally-tailored indigenous heat-mitigating balanced diet as once a day meal starting from at least one month before conception and throughout the pregnancy till delivery.
The uniqueness of this intervention lies in its culturally-preservative approach, its novel target of heat stress, its timing (preconception), and its integrated process (nutritionist collaboration + overall dietary counseling). It specifically targets heat resilience in pregnancy through a holistic approach of adapting dietary intervention as mitigating strategy for providing resilience to heat stress and evaluating key hypothesized pathways responsible for combating adverse pregnancy outcomes by this intervention.
No Intervention: Usual Diet Arm
Pregnant women in this arm will continue with their usual diet, and receives standard antenatal care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in proportion of neonates with low Weight-for-Gestational-Age Z-score (WGAZ< -2 SD) at birth between intervention and control arms.
Time Frame: Within 24 hours of delivery

Neonatal birth weight (grams) will be measured using a digital infant weighing scale within 24 hours of birth. Birth weight will be converted into WGAZ using WHO 2013 sex- and gestational age-specific reference standards. The percentage of neonates with low WGAZ (< -2 SD) will be calculated for both supplemented and non-supplemented groups, and comparisons between groups will be made using appropriate statistical methods, adjusting for maternal heat stress exposure.

Unit of Measure: % of neonates with WGAZ < -2 SD

Within 24 hours of delivery
Difference in proportion of neonates with low height-for-Gestational-Age Z-score (LGAZ< -2 SD) at birth between intervention and control arms.
Time Frame: Within 24 hours of delivery

Neonatal birth height (cm) will be measured using a standardized neonate's height scale within 24 hours of birth. Birth height will be converted into LGAZ using WHO 2013 sex- and gestational age-specific reference standards. The percentage of neonates with low LGAZ (< -2 SD) will be calculated for both supplemented and non-supplemented groups, and comparisons between groups will be made using appropriate statistical methods, adjusting for maternal heat stress exposure.

Unit of Measure: % of neonates with LGAZ < -2 SD

Within 24 hours of delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gestational age at delivery
Time Frame: At delivery date

Gestational age will be determined based on first-trimester ultrasound and/or last menstrual period (LMP).

Unit of Measure: Weeks

At delivery date
Mode of delivery
Time Frame: At delivery
Mode of delivery will be recorded as vaginal or cesarean section. Unit of Measure: Percentage (%) of cesarean deliveries
At delivery
Maternal serum ferritin concentration
Time Frame: Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.

Maternal serum ferritin will be measured using standardized immunoturbidimetric assay on an automated chemistry analyzer.

Unit of Measure: ng/mL

Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Maternal serum folate concentration
Time Frame: Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Maternal serum folate will be measured using standardized laboratory assay on automated immunoassay analyzer.
Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Maternal serum 25-hydroxyvitamin D concentration
Time Frame: Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.

Maternal serum 25-hydroxyvitamin D concentration will be measured using standardized laboratory assay on automated immunoassay analyzer.

Unit of Measure: ng/mL

Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Generalized anxiety symptoms
Time Frame: Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.

Maternal mental health will be assessed using a validated psychological questionnaires Generalized Anxiety Disorder-7 (GAD-7) for assessing generalized anxiety symptoms over the past two weeks.

Unit of Measure: The scale comprises 7 items, each rated on a 4-point Likert scale from 0 (not at all) to 3 (almost every day), with a total score ranging from 0 to 21.

Interpretation: A score of 15 or higher is indicative of severe anxiety.

Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Maternal gut microbiome alpha diversity
Time Frame: Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.

Alpha diversity of maternal gut microbiome will be assessed using 16S rRNA gene sequencing of stool samples.

Unit of Measure: Shannon diversity index

Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Placental gene expression levels
Time Frame: At delivery

Placental gene expression will be quantified using RNA sequencing. Expression levels will be reported as normalized transcript counts.

Unit of Measure: Normalized transcript counts

At delivery
Estimated fetal weight during pregnancy
Time Frame: Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.

Estimated fetal weight will be calculated using ultrasound biometric measurements according to standard obstetric formulas.

Unit of Measure: Grams

Evaluated at the end of each trimester (within one week before or after the scheduled time point), from enrollment until delivery.
Perceived stress score
Time Frame: Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).

Perceived Stress Scale-10 (PSS-10) to assess perceived stress over the past month.

Unit of Measure: The scale consists of 10 items, each rated on a 5-point Likert scale from 0 (never) to 4 (very often), with a total score ranging from 0 to 40.

Interpretation: A score of 27 or higher indicates higher perceived stress.

Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).
Postnatal depression symptoms
Time Frame: Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).

Edinburgh Postnatal Depression Scale (EPDS) to assess postnatal depression symptoms over the past week.

Unit of Measure: The scale comprises 10 items, each rated on a 4-point Likert scale from 0 (no) to 3 (yes), with a total score ranging from 0 to 30.

Interpretation: A score of 13 or greater is indicative of postnatal depression.

Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).
Depression symptoms
Time Frame: Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).

Patient Health Questionnaire-9 (PHQ-9) to assess depression symptoms over the past two weeks.

Unit of Measure: The scale consists of 9 items, each rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.

Interpretation: A score of 10 or greater indicates moderate to severe depression.

Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).
Combined Depression, Anxiety, and Stress score
Time Frame: Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).

Depression, Anxiety, and Stress Scale-21 (DASS-21) to Assesses depression, anxiety, and stress over the past week.

Unit of Measure: The scale consists of 21 items, divided into three subscales, each rated on a 4-point Likert scale from 0 (did not apply to me at all) to 3 (applied to me most of the time). Each subscale score is multiplied by 2 to match the original DASS-42 format.

Interpretation: A score of 14 or greater is indicative of moderate to severe depression, anxiety, and stress.

Assessed at enrollment (baseline), monthly during pregnancy, and postpartum (after 2 weeks of delivery).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Junaid Iqbal, PhD, Aga Khan University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

November 28, 2025

First Submitted That Met QC Criteria

March 19, 2026

First Posted (Actual)

March 24, 2026

Study Record Updates

Last Update Posted (Actual)

March 24, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 10697-33069
  • 074884 (Other Grant/Funding Number: Bill & Melinda Gates Foundation)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual Participant Data (IPD) will not be made available to anyone including other researchers. Participant confidentiality and privacy protection will be given utmost importance as even anonymized data could have potential indirect identifiers due to the particular locality of the study in a specific rural community, which may lead to the re-identification of participants and may damage the reputation of the community, or stigmatize the participants. Informed consent was also not obtained from the participants regarding sharing of personal data with the public. Thus, we will prioritize our ethical commitment by only making available results of the study in aggregated group format.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy

Clinical Trials on Indigenous Balanced Diet Arm

Subscribe